ZIOPHARM Oncology begins public offering of common stock

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a public offering. JMP Securities LLC and Rodman & Renshaw, LLC are acting as co-lead managers for the offering.

The Company plans to use net proceeds from this offering for general corporate purposes, which may include ongoing clinical development of its three product candidates, palifosfamide (Zymafos^TM or ZIO-201), darinaparsin (Zinapar^TM or ZIO-101), and indibulin (Zybulin^TM or ZIO-301).

The offering is being made pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (File No. 333-161453). A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting JMP Securities LLC at Equity Syndicate, 600 Montgomery Street, Suite 1100, San Francisco, CA 94111; (415) 835-8900.